NPCE — NeuroPace Inc
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-04-22.
Performance
Technicals
Others in Healthcare
Measured signals that fired on NPCE
| date | signal | measured base rate |
|---|---|---|
| 2026-05-07 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-03-31 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-03-02 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-24 | Morrell Martha CHIEF MEDICAL OFFICER | Shares withheld for tax | 335 | 16.22 | 5.4K |
| 2026-06-19 | Fischer Frank M Director | Grant or award | 1.5K | 15.63 | 22.9K |
| 2026-06-19 | Kumar Rakhi Director | Grant or award | 989 | 15.63 | 15.5K |
| 2026-06-19 | Geiger Uri Director | Grant or award | 789 | 15.63 | 12.3K |
| 2026-06-05 | Fischer Frank M Director | Grant or award | 2.9K | 0.00 | 0 |
| 2026-06-05 | Geiger Uri Director | Grant or award | 2.9K | 0.00 | 0 |
| 2026-06-05 | Ryan Renee Director | Grant or award | 2.9K | 0.00 | 0 |
| 2026-06-05 | Kumar Rakhi Director | Grant or award | 2.9K | 0.00 | 0 |
| 2026-06-05 | Huennekens R Scott Director | Grant or award | 2.9K | 0.00 | 0 |
| 2026-06-05 | Andrade Lisa Director | Grant or award | 2.9K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Polar Capital Holdings Plc | 43.4M | 3.3M |
| Soleus Capital Management, L.P. | 38.6M | 2.9M |
| MORGAN STANLEY | 33.8M | 2.6M |
| First Light Asset Management, LLC | 32.3M | 2.5M |
| BlackRock, Inc. | 30.9M | 2.3M |
| ORBIMED ADVISORS LLC | 27.6M | 2.1M |
| Driehaus Capital Management LLC | 19.1M | 1.5M |
| VANGUARD CAPITAL MANAGEMENT LLC | 14.8M | 1.1M |
| DEUTSCHE BANK AG\ | 12.3M | 932.1K |
| ARMISTICE CAPITAL, LLC | 9.1M | 692.0K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Neuropace Inc (NPCE) filed form 8-K · 2026-08-11 · SEC EDGAR
Ask the AI about NPCE
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →